MBX 2109
MBX-2H1002
Phase 2 small_molecule completed
Quick answer
MBX 2109 for Hypoparathyroidism is a Phase 2 program (small_molecule) at MBX Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- MBX Biosciences
- Indication
- Hypoparathyroidism
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed